Abstract Large scale association studies have identified low penetrance susceptibility alleles that predispose to breast cancer. A locus on chromosome 8q24.21 has been shown to harbour variants that predispose to breast, ovarian, colorectal and prostate cancer. The finding of risk variants clustering at 8q24 suggests that there may be common susceptibility alleles that predispose to more than one epithelial cancer. The aim of this study was firstly to determine whether previously identified breast cancer susceptibility alleles are associated with sporadic breast cancer in the West of Ireland and secondly to ascertain whether there are susceptibility alleles that predispose to all three common epithelial cancers (breast, prostate, colon). We genotyped a panel of 24 SNPs that have recently been shown to predispose to prostate, colorectal or breast cancer in 988 sporadic breast cancer cases and 1,016 controls from the West of Ireland. We then combined our data with publicly available datasets using standard techniques of meta-analysis. The known breast cancer SNPs rs13281615, rs2981582 and rs3803662 were confirmed as associated with breast cancer risk (P allelic test = 1.8 9 10 -2 , OR = 1.17; P allelic test = 2.2 9 10 -3 , OR = 1.22; P allelic test = 5.1 9 10 -2 , OR = 1.15, respectively) in the West of Ireland cohort. For the remaining five breast cancer SNPs that were studied there was no evidence of an association with breast cancer in the West Ireland population (P allelic test [ 6.5 9 10 -2
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Introduction
The risk of breast cancer is raised about twofold in the sisters and mothers of affected women. Only a small proportion of this risk is accounted for by known breast cancer predisposition genes such as BRCA1 and BRCA2. The search for further high penetrance genes has failed to identify loci that predispose to breast cancer, suggesting that less penetrant genes may be important. Despite the identification of rare alleles that confer a modestly increased risk of breast cancer-such as CHEK2, ATM, BRIP and PALB2-about 75% of the familial risk remains unexplained [1] . A polygenic model for susceptibility to breast cancer and other common cancers, including colorectal and prostate cancer, has been suggested, where risk is conferred by a large number of alleles, each conferring a small risk, but which, when combined, confer a range of susceptibilities within the population [2] .
In order to identify common, low penetrance cancer susceptibility alleles, large genome-wide association studies (GWAS) have been performed. Easton et al. identified five loci associated with increased risk of developing breast cancer. These were initially identified in breast cancer patients with a family history and verified in a much larger cohort of patients with both sporadic and familial breast cancer [3] . The SNPs with the strongest association with breast cancer in this study were rs2981582 (10q: FGFR2), rs3803662 (16q:TNRC9) and rs13281615 (chr8q24) with a per allele OR typically of 1.1-1. 26 . Several other studies have also identified an association with SNPs within FGFR2 and TNRC9 and breast cancer [4, 5] . More recent studies have also identified SNPs in other regions that predispose to breast cancer. SNPs on 2q35 (rs13387042) and 5p12 (rs4415084 and rs10941679) have been shown to be associated with estrogen-receptor (ER) positive breast cancer [5, 6] and SNPs lying within cell cycle genes have been shown to be associated with breast cancer in the British population (rs997669 in CCNE1, rs3176336 in CDKN1A, rs34330 in CDKN1B and rs3731239 in CDKN2A/2B) [7] . These associations have yet to be confirmed in other studies or populations, with the exception of rs34330, which has been shown to be associated with breast cancer in the Chinese population [8] .
One of the breast cancer susceptibility SNPs identified by Easton et al. rs13281615 (chr8:128,424,800), lies at chromosome 8q24.21, a region that is also associated with colorectal and prostate cancer risk. Within 8q24.21, several GWASs have shown an association between prostate cancer and SNP rs1447295 (chr8:128,553,970) [9] [10] [11] [12] [13] . This locus has been studied in breast cancer cohorts, but no association found [14] . A second independent locus within 8q24 conferring prostate cancer risk, rs16901979 (chr8:128,194,098), has been identified [11, 12] . Another nearby SNP, rs6983267 (chr8:128,482,237), confers an increased risk of colorectal cancer [15, 16] and also confers some independent prostate cancer risk and ovarian cancer risk [17] . The association with prostate cancer is weaker than that with rs1447295 [18] , but again independent of both rs1447295 and rs16901979. All four SNPs are found within 400 kb of each other: rs13281615 is 130 kb proximal of rs1447295, 60 kb proximal of rs6983267 and 230 kb distal of rs16901979.
Many of the common cancers are associated with a twofold increase in familial relative risk across the different cancer types [19] . This together with the finding of risk variants for breast, prostate, colon and ovarian cancer clustering at 8q24 suggests that there may be low penetrance susceptibility alleles elsewhere in the genome predisposing to all of these cancers. Large genome wide association studies of prostate and colorectal cancer have now identified new prostate [20] [21] [22] and colorectal [23] [24] [25] [26] [27] susceptibility alleles in addition to the alleles at 8q24. It is not known whether these alleles also predispose to breast cancer.
The aims of this study were:
1. To confirm whether recently identified breast cancer predisposition SNPs also predispose to breast cancer in the Irish population. 2. To determine whether any of the other known cancer SNPs, also predispose, perhaps more weakly, to other common cancer types.
Methods
A total of 988 breast cancer cases and 1,016 controls from the West of Ireland were collected with appropriate ethical approval as part of the Breast cancer in Galway Genetics Study (BIGGS). This population shares similar ethnic ancestry to the population in the UK, but has been subject to fewer demographic movements [28] . Consequently, this population is relatively homogenous, which reduces allelic and genotypic heterogeneity in case-control studies. The results are also likely to be relevant to several other populations of European ancestry. The mean age of the cases at diagnosis was 53 years (range 24-90 years). They were not selected with regard to family history of breast or ovarian cancer, personal history of ovarian cancer, the presence of a contralateral breast cancer or other second primary cancer (122 patients had a first degree relative with breast cancer, mean age 53.5 years; 153 had a second degree relative with breast cancer, mean age 50.5 years; and 40 had bilateral breast cancer, mean age 53.5 years). All controls were from a West of Ireland lineage (as were cases) and comprised women over the age of 60 years, with no selfreported personal history of any cancer and no family history of breast or ovarian cancer. The power of our study, based on reasonable assumptions from previous studies, for the breast cancer SNPs rs2981582, rs3803662 and rs13281615, was as follows. Using an allelic test, 988 cases and 1,016 controls provided [90% power at P \ 0.05 (two-tailed test) to detect a SNP allele with a frequency of 0.4 associated with an OR of 1.3; [60% power to detect an allele of frequency of 0.25 associated with an OR of 1.2; and *30% power to detect an allele of frequency 0.4 associated with an OR of 1.1.
DNA was extracted from blood using the Chemagic Magnetic Separation Module (Chemagen, Baesweiler, Germany) using the manufacturers reagents. A panel of 24 breast cancer, colorectal cancer and prostate cancer susceptibility loci were genotyped using the KASPar SNP genotyping system (KBiosciences), Table 1 . Primers are available on request. A subset of samples were sequenced for each SNP to confirm the results. Sequencing was performed using the ABI 3100 automated sequencer and sequence analysis software (Applied Biosystems, CA).
Deviation of genotype frequencies from those expected under Hardy-Weinberg equilibrium (HWE) was assessed by v 2 test, or Fisher's exact test where an expected cell count was \5. The risk associated with each SNP was estimated by allelic, dominant and recessive odds ratio (OR) and associated 95% confidence intervals (CI). Genotypic ORs were determined by logistic regression.
Determination of a general cancer risk allele was performed by meta-analysis using publicly available SNP data for breast and prostate cancer (CGEMS, http://cgems.
cancer.gov/: breast study-1,183 postmenopausal cases and 1,185 controls; prostate study-1,177 cases and 1,105 controls) and SNP data from the first phase of our colorectal cancer GWAS (930 familial colorectal tumour cases and 960 controls) [15] . Data from these breast, prostate and colorectal cancer samples were combined with the West of Ireland cohort to derive an overall estimate of cancer risk using a fixed effects model with inverse variance weighting of individual studies. Reported predisposition SNPs not found on the Illumina platform data were imputed using IMPUTE [29] . Bias was assessed using the I 2 and Q estimates. For any significant findings in the fixed effects model with values I 2 C 50% (considered moderate heterogeneity [30] ), the analysis was repeated using a random effects model. All statistical analyses were undertaken using STATA 9.2 (Stata Corp, College Station, TX).
Results

Verification of reported breast cancer SNPs in the BIGGS study
Samples that consistently failed in [20% of the SNPs studied were excluded from the analysis (25 cases, 20 We used a threshold of P B 0.05 (two-tailed) for replication of previous studies. Of the five breast cancer loci previously identified by Easton et al. only rs2981582 (FGFR2) and rs13281615 (8q24) showed an association with breast cancer in the West of Ireland population at P \ 0.05, Table 2a . There was a borderline association with rs3803662 (TNRC9) at P allelic test = 5.1 9 10 -2 . rs2981582 showed the strongest association with breast cancer, allelic test of association (P = 1.8 9 10 -2 , Table 2a ) and the genotypic test (P = 2 9 10 -3 , Table 2a ). The odds ratio (OR) for the TT homozygote was 1.489 (95% CI 1.153-1.922, P = 2 9 10 -3 ) and that for the CT heterozygote was 1.176 (95% CI 0.958-1.443, P = 1 9 10 -1 ), relative to the CC homozygote in each case. The association between rs13281615 and breast cancer was also confirmed using the allelic test of association (P = 1.8 9 10 -2 , Table 2a ) and the genotypic test (P = 0.026, Table 2a ). The odds ratio (OR) for the GG homozygote was 1.28 (95% CI 0.98-1.66, P = 7 9 10 -2 ) and that for the AG heterozygote was 1.34 (95% CI 1.09-1.64, P = 6 9 10 -3 ) relative to the AA homozygote. There was a borderline association between rs3803662 and breast cancer (allelic test of association, P = 1.8 9 10 -2 and the genotypic test, P = 4.7 9 10 -2 , Table 2a ). The odds ratio (OR) for the TT homozygote was 1.554 (95% CI 1.09-2.23, P = 1.6 9 10 -2 ) and that for the CT heterozygote was 1.060 (95% CI 0.88-1.278, P = 5.7 9 10 -1 ), relative to the CC homozygote in each case. rs889312 (MAP3K1) and rs3817198 (LSP1) showed no association with breast cancer in this population (P allelic test = 2.4 9 10 -1 , P allelic test = 5.4 9 10 -1 , respectively). There was also no evidence of an association with the cell cycle gene SNPs (rs997669, rs3176336, rs34330) or rs4415084 (5p12) that have recently been suggested as breast cancer predisposition SNPs. It is not clear whether these differences are due to the different population studied or due to a lack of power in this study to detect these weaker associations. In order to answer this question we performed a meta-analysis on those SNPs where there was publicly available data in breast cancer, Table 3 . This confirmed the association with rs4415084 (5p12) and rs3176336 (CDKN1A) also showed a significant association with breast cancer. However, the latter finding was based only on data from two studies (SEARCH and BIGGS) as there was no data available from CGEMS for this SNP. There was no evidence of an association between breast cancer and rs34330 (CDKN1B), rs997669 (CCNE1) or rs3817198 (LSP1), Table 3 .
Association between breast cancer SNPs and clinicopatholgical features of breast cancer Histological information was available on 795 (80%) cases and is summarised in Table 4 . Univariate analysis showed evidence of an association between rs2981582 and PR positivity (P = 3.5 9 10 -2 ), but not ER positivity (P = 1.0 9 10 -1 ). Univariate analysis also showed a negative association between rs3803662 and her two positivity (P = 3.7 9 10 -2 ), but no evidence of an association with ER/PR status. There was no evidence of an association between the rs13281615 risk allele and ER status, Her2 positivity, grade, nodal status or bilaterality. There was however an association with age and rs13281615 with younger cases more likely to have the at risk allele (P = 4.1 9 10 -2 ).
Analysis of colorectal and prostate SNPs in the BIGGS study
The prostate and colorectal SNPs on 8q24 showed no association with breast cancer in our cohort and there was no association with any of the other low penetrance colorectal and prostate SNPs that were studied for any of the genetic models tested (Table 2b , c for allelic and genotypic tests). Logistic regression analysis provided no evidence for an independent effect of the colorectal or prostate SNPs studied on breast cancer risk (details not shown).
Meta-analysis to search for general cancer predisposition alleles for the three common cancers
We performed a meta-analysis in order to try and ascertain whether there was any evidence of a general cancer predisposition allele. A comprehensive list of SNPs known to confer an increased cancer risk of either breast, colorectal and prostate cancer was compiled ( Table 5) . As all publicly available data were based on the Illumina platform, reported predisposition SNPs not found on the Illumina platform data were imputed using IMPUTE [29] (rs4666451, rs981782, rs2180341, rs13281615, rs1045485). In the case of rs2981582 (FGFR2), we used a previously identified Illumina SNP (rs1219648) at this locus which has also been shown to be associated with the breast cancer [4] . Two SNPs (rs3176336 and rs889312) previously shown to predispose to breast cancer could not be imputed due to lack of HapMap data. Data from publicly available sources (see ''Methods'') on genotype frequencies in cases and controls for these risk SNPs were combined using a fixed effects model for allelic, genotypic, recessive and dominant modes of risk. Only one SNP (rs6983267 on 8q24, P \ 5 9 10 -4 ) conferred risk to cancer in two tissue types (CRC and prostate cancer), as previously published [15, 16] . Of the remaining 31 SNPs analysed (5 associated with CRC risk, 13 with breast cancer, 13 with prostate cancer), none were significantly associated with cancer risk in another tumour type, either on its own or in combination of those tissue types in which the SNP was not discovered (Supplementary Table 1 ). 
Discussion
We have provided replication of the association between rs2981582, rs13281615, and rs3803662 and breast cancer susceptibility in a sporadic breast cancer cohort from the West of Ireland. Unlike many previous studies, cases were not selected for family history of breast cancer [3] or enriched for bilateral breast cancers [31] . The allelic ORs detected in this study for both rs2981582 and rs3803662 were similar to that detected by Easton et A previous study showed that the rs2981582 risk allele had a stronger association with ER and PR positive breast cancers than ER negative breast cancers [32] . A similar but weaker association was found for rs13281615 and rs3803662 [32] . We only found an association between PRpositive tumours and rs2981582 on univariate analysis. ER and PR status showed no association with rs13281615 and rs3803662 in this study. We did however find a negative association between rs3803662 and her two positivity and an association between age of breast cancer diagnosis and rs13281615, with younger breast cancer patients more likely to have the risk allele.
In the study by Easton et al. rs889312 (MAP3K1) and rs3817198 (LSP1) showed a weaker association with breast cancer than rs2981582, rs13281615, and rs3803662.
Neither of these SNPs showed evidence of an association in BIGGS. We also found no evidence of an association between SNPs found within cell cycle genes and the West of Ireland breast cancer population, and did not verify the findings of Stacey et al. of a breast cancer predisposition SNP on 5p12. The latter association was only found in ER positive breast cancers. When we confined our analysis to this subgroup of breast cancer, we found no association with the 5p12 SNP, rs4415084, but did find an association between rs3176336, rs4779584 and rs7931342 and ER positive breast cancer (P allelic test = 0.02, P allelic test = 0.03, P allelic test = 0.03, respectively), but this may represent modulation of phenotype, not susceptibility. The explanation for some of these differences is due to the power of our study as when we performed a meta-analysis combining our data with publicly available data we did confirm the association with rs4415084 (5p12), but not for rs34330, rs997669 or rs3817198.
We have performed a comprehensive meta-analysis of alleles that predispose to breast, prostate and colorectal cancer in order to test whether they are general carcinoma susceptibility loci. This showed that only one SNP (rs6983267 on 8q24) conferred risk to cancer in two tissue types (colorectal cancer and prostate cancer). Importantly, rs6983267 was not associated with an increase in breast cancer risk despite the known association of breast cancer with that region, overall, our data suggest that low penetrance susceptibility SNPs for breast, prostate and colorectal cancer are distinct leaving open the exploration for the increase in familial relative risk across the cancer types.
The most recent SNP found to predispose to colorectal cancer is rs9929218 which is located in intron1 of CDH1 (E-cadherin) [27] . A SNP in the E-cadherin promoter (-160C ? A) has previously been shown to be associated with prostate cancer [33] . However, the CGEMS prostate cancer study showed no evidence of an association with rs9929218 and prostate cancer. Loss of E-cadherin expression is characteristic of invasive lobular breast cancers [34] and germline mutations have been found in some familial lobular carcinomas [35] . There was no evidence of an association between rs9929218 and lobular cancer in the BIGGS cohort, however the study does not have the power to detect such an association if it existed with only 106 invasive lobular cancers in this series.
The finding of risk variants clustering at 8q24 is intriguing, our data and that of Fletcher et al. suggest that these variants are organ specific. Telomeric to the rs16901979 and rs13281615 haplotype blocks on 8q24 lie the expressed transcript POU5F1P1 (128.50 Mb), that has potential to encode a homologue of the transcription factor OCT4, and the oncogene MYC (128.82 Mb). It remains possible that combinations of different genomic control regions involved in regulating MYC or POU5F1P1 expression are associated with susceptibility to different types of the common cancers. It has been proposed that variation at putative 8q24 cis-regulator(s) of transcription can significantly alter germline c-MYC expression levels and, thus, contribute to cancer susceptibility [36] . In conclusion we have confirmed that SNPs close to FGFR2 and TNCR9 and at 8q24(128424800) predispose to sporadic breast cancer in the West of Ireland. However, we have failed to replicate the association of SNPs close to MAP3K1, LSP1, CCNE1, CDKN1A, CDKN1B and at 5p12 in this population. We have shown that there is no association between the recently identified colorectal and prostate cancer SNPs and breast cancer. In general, prostate and colorectal cancer susceptibility alleles are site specific, despite some clustering at 8q24.
